Talon delivers NDA to US FDA for Marqibo in adult Ph- ALL
This article was originally published in Scrip
Executive Summary
Talon Therapeutics submitted a new drug application to the US FDA for Marqibo (vincristine sulfate liposomes injection) seeking accelerated approval to market the drug as a treatment for patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL), in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy.